| Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|
 | SHR | 95% CI | p | SHR | 95% CI | p |
Demographic characteristics | ||||||
 Age at entry (per 5 years increase) | 1.06 | 0.97-1.17 | 0.193 | 1.07 | 0.99-1.04 | 0.174 |
 Female gender | 0.73 | 0.34-1.59 | 0.433 | 0.92 | 0.38-2.23 | 0.859 |
 BMI (per 5 kg/m2 increase) | 1.22 | 0.94-1.58 | 0.131 | 1.30 | 0.94-1.80 | 0.112 |
Clinical history | ||||||
 Prior history of thrombosis | 0.94 | 0.45-1.95 | 0.865 | 1.40 | 0.60-3.27 | 0.436 |
-Arterial | 1.31 | 0.55-3.12 | 0.547 | 1.08 | 0.42-2.79 | 0.872 |
-Venous | 0.73 | 0.37-1.46 | 0.374 | 1.06 | 0.51-2.20 | 0.870 |
-Arterial and venous | 0.53 | 0.09-3.23 | 0.491 | 0.38 | 0.04-3.79 | 0.409 |
 Prior history of pregnancy complicationsa | 0.97 | 0.39-2.40 | 0.954 | 0.53 | 0.19-1.48 | 0.225 |
 APS | 0.75 | 0.36-1.58 | 0.448 | 0.89 | 0.39-2.00 | 0.772 |
 Family history of thrombosis | 0.70 | 0.31-1.57 | 0.390 | 0.86 | 0.37-2.00 | 0.719 |
 Oral anticoagulation at baseline (VKA) | 0.93 | 0.47-1.86 | 0.839 | 1.16 | 0.56-2.39 | 0.695 |
Comorbidities | ||||||
 Hypertension | 1.28 | 0.60-2.75 | 0.525 | 0.79 | 0.25-2.53 | 0.697 |
 Diabetes | 5.18 | 1.87-14.31 | 0.002 | N/A | N/A | N/A |
 Statin exposure | 2.64 | 0.71-9.82 | 0.147 | 3.34 | 0.94-11.89 | 0.063 |
 Autoimmune rheumatic diseasesb | 0.81 | 0.38-1.74 | 0.594 | 0.70 | 0.31-1.60 | 0.404 |
 Hereditary thrombophiliac | 1.22 | 0.60-2.46 | 0.586 | 1.23 | 0.59-2.55 | 0.580 |
 Active smoker at baseline | 2.11 | 1.06-4.20 | 0.034 | N/A | N/A | N/A |
Disease-defining autoantibodies | ||||||
 aPTT-LA (per 10-s increase) | 1.10 | 1.00-1.21 | 0.044 | N/A | N/A | N/A |
 aPTT ratio (per 1 multiple of the mean) | 1.39 | 1.01-1.93 | 0.044 | N/A | N/A | N/A |
 aPTT or aPTT ratio >75th percentiled | 2.65 | 1.32-5.31 | 0.006 | N/A | N/A | N/A |
 aβ2-GPI IgM (per 1 logMPL increase) | 1.12 | 0.87-1.46 | 0.377 | 1.00 | 0.75-1.33 | 0.993 |
 aβ2-GPI IgG (per 1 logGPL increase) | 1.03 | 0.85-1.25 | 0.778 | 1.04 | 0.84-1.28 | 0.730 |
 aCL IgM (per 1 logMPL increase) | 1.30 | 0.98-1.74 | 0.068 | 1.08 | 0.76-1.53 | 0.665 |
 aCL IgG (per 1 logGPL increase) | 1.10 | 0.87-1.39 | 0.436 | 1.03 | 0.80-1.33 | 0.804 |
 LA alone | 0.77 | 0.35-1.71 | 0.528 | 0.91 | 0.41-2.02 | 0.825 |
 LA + aβ2-GPI | 1.33 | 0.60-2.95 | 0.476 | 1.14 | 0.51-2.53 | 0.746 |
 LA + aCL | 1.42 | 0.71-2.82 | 0.323 | 1.16 | 0.56-2.42 | 0.684 |
 Triple positivity (ISTH cut-off)e | 1.53 | 0.77-3.04 | 0.226 | 1.22 | 0.58-2.54 | 0.598 |
 Triple positivity (Padova cut-off)e | 1.37 | 0.67-2.84 | 0.390 | 1.00 | 0.45-2.23 | 0.998 |
 Triple positivity (local cut-off)e | 1.21 | 0.59-2.51 | 0.603 | 0.91 | 0.42-1.99 | 0.812 |
LA-related autoantibodies | ||||||
 Domain I β2-GPI (per 1000 CU increase) | 0.93 | 0.65-1.34 | 0.711 | 0.82 | 0.43-1.56 | 0.546 |
 Anti-protein Z IgM (per 10 units increase) | 1.00 | 0.58-1.72 | 0.999 | 0.75 | 0.43-1.30 | 0.301 |
 Anti-protein Z IgG (per 10 units increase) | 1.01 | 0.74-1.38 | 0.931 | 0.90 | 0.67-1.20 | 0.457 |
 Antiprothrombin IgM | 0.98 | 0.87-1.10 | 0.747 | 0.98 | 0.94-1.01 | 0.163 |
 Antiprothrombin IgG | 0.99 | 0.96-1.01 | 0.373 | 1.00 | 0.99-1.00 | 0.340 |
 Annexin A5 ratio (per 50% increase) | 0.83 | 0.56-1.23 | 0.347 | 0.92 | 0.55-1.53 | 0.734 |
Selected laboratory parameters | ||||||
 C-reactive protein (per 5 mg/dL increase) | 1.04 | 0.68-1.57 | 0.863 | 0.95 | 0.63-1.42 | 0.792 |
 Triglycerides (per 100 mg/dL increase)f | 1.32 | 0.86-2.01 | 0.201 | 1.19 | 0.96-1.47 | 0.121 |
 Cholesterol (per 100 mg/dL increase) | 1.22 | 0.58-2.58 | 0.604 | 1.31 | 0.59-2.92 | 0.513 |
 HDL/LDL ratio (per 1 unit increase) | 0.99 | 0.82-1.20 | 0.937 | 1.04 | 0.89-1.21 | 0.601 |
 Homocysteine (per 5 μmol/L increase)f | 1.25 | 0.81-1.93 | 0.316 | 1.03 | 0.94-1.12 | 0.571 |
 Fibrinogen (per 100 mg/dL increase) | 1.15 | 0.80-1.66 | 0.440 | 1.23 | 0.86-1.77 | 0.253 |